The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology.
Fuente : http://www.eurekalert.org/pub_releases/2013-06/msc...
Fuente : http://www.eurekalert.org/pub_releases/2013-06/msc...